Clinicopathologic Study of Pineal Parenchymal Tumors of Intermediate Differentiation

被引:30
|
作者
Ito, Tamio [1 ]
Kanno, Hiromi [3 ]
Sato, Ken-ichi [1 ]
Oikawa, Mitsuteru [1 ]
Ozaki, Yoshimaru [1 ]
Nakamura, Hirohiko [1 ]
Terasaka, Shunsuke [2 ]
Kobayashi, Hiroyuki [2 ]
Houkin, Kiyohiro [2 ]
Hatanaka, Kanako [4 ]
Murata, Jyun-ichi [5 ]
Tanaka, Shinya [3 ]
机构
[1] Nakamura Mem Hosp, Brain Tumor Ctr, Dept Neurosurg, Sapporo, Hokkaido, Japan
[2] Hokkaido Univ, Sch Med, Dept Neurosurg, Sapporo, Hokkaido 060, Japan
[3] Hokkaido Univ, Sch Med, Dept Canc Pathol, Sapporo, Hokkaido 060, Japan
[4] Hokkaido Univ Hosp, Dept Canc Pathol, Sapporo, Hokkaido 060, Japan
[5] Sapporo Azabu Neurosurg Hosp, Sapporo, Hokkaido, Japan
关键词
MIB-1 labeling index; Neuronal marker; Pineal parenchymal tumor; PPTID; Radiotherapy; ADULT PATIENTS; PINEALOBLASTOMA; MANAGEMENT;
D O I
10.1016/j.wneu.2013.02.007
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE: Pineal parenchymal tumors of intermediate differentiation (PPTID) are extremely rare tumor entities, and only limited data are available regarding their pathologic features and biologic behaviors. Because grading criteria of pineal parenchymal tumors (PPTs) have yet to be established, the treatment strategy and prognosis of PPTIDs remain controversial. We describe the clinicopathologic study of six patients with PPTID and compare responses for the treatment and prognosis with cases of pineocytoma (PC) and pine-oblastoma (PB). From this analysis, we attempt to clarify the treatment strategy for PPTIDs. METHODS: This study included 15 patients with PPTs, consisting of 6 PCs, 6 PPTIDs, and 3 PBs. We focused on the 6 patients with PPTIDs. All PPTID cases were treated surgically, and radiotherapy and chemotherapy were administered as adjuvant therapies in some cases. We have earlier reported the histopathologic study (Neuropathology 32: 647-653, 2012). Briefly, we examined mitotic figures and necrosis by hematoxylin-eosin staining and immunohistochemical markers such as neuronal markers (synaptophysin, neurofilament (NF), and neuronal nuclear antigen), and an MIB-1 labeling index was determined. RESULTS: In the PPTID cases, the extent of resection was variable and the recurrence rates among patients varied according to stage and treatment. All PC patients underwent total resection with no recurrence. All PB patients underwent resection and adjuvant therapy with radiotherapy and chemotherapy. There were no recurrences in patients with PC or PB. The results of histopathologic findings have been already reported as mentioned above. Briefly, the results indicated no mitotic figure or necrosis in any of the six cases of PPTID, but those features were observed in PB cases. All cases even including PC and PB were immunopositive for neuronal markers. The MIB-1 labeling index of PPTID was 3.5%, whereas it was 0% in PC and 10.5% in PB. CONCLUSIONS: Good radiosensitivity of PPTIDs was observed in our series. Because there are cases with discrepancies between images and pathologic findings, it is very difficult to determine the proper treatment strategy for PPTIDs. Proliferative potential was correlated with World Health Organization grade, although the immunoreactivity of neuronal markers did not correlate with the histologic grade.
引用
收藏
页码:783 / 789
页数:7
相关论文
共 50 条
  • [1] ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation
    Martinez, Haydee
    Nagurney, Michelle
    Wang, Zi-Xuan
    Eberhart, Charles G.
    Heaphy, Christopher M.
    Curtis, Mark T.
    Rodriguez, Fausto J.
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2019, 78 (08): : 703 - 708
  • [2] Pineocytoma and pineal parenchymal tumors of intermediate differentiation presenting cytologic pleomorphism:: A multicenter study
    Fevre-Montange, Michelle
    Szathmari, Alexandru
    Champier, Jacques
    Mokhtari, Karima
    Chretien, Fabrice
    Coulon, Alix
    Figarella-Branger, Dominique
    Polivka, Marc
    Varlet, Pascale
    Uro-Coste, Emmanuelle
    Fauchon, Francois
    Jouvet, Anne
    [J]. BRAIN PATHOLOGY, 2008, 18 (03) : 354 - 359
  • [3] Pineal parenchymal tumor of intermediate differentiation with papillary features: a continuum of primary pineal tumors?
    Cohan, Jessica N.
    Moliterno, Jennifer A.
    Mok, Christina L.
    Lavi, Ehud
    Boockvar, John A.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2011, 101 (02) : 301 - 306
  • [4] Pineal parenchymal tumor of intermediate differentiation with papillary features: a continuum of primary pineal tumors?
    Jessica N. Cohan
    Jennifer A. Moliterno
    Christina L. Mok
    Ehud Lavi
    John A. Boockvar
    [J]. Journal of Neuro-Oncology, 2011, 101 : 301 - 306
  • [5] Pineal Parenchymal Tumors With Intermediate Differentiation to Pineoblastoma: A Transitional Neuroectodermal Tumor of the Pineal Gland
    Jha, Pooja
    Shukla, Samarth
    Vagha, Sunita
    Acharya, Sourya
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
  • [6] Clinicopathologic features of pineal parenchymal tumors in a single institutional study
    Sasaki, A.
    Ishizawa, K.
    Shimizu, M.
    Nishikawa, R.
    Honma, T.
    [J]. BRAIN PATHOLOGY, 2014, 24 : 87 - 87
  • [7] Pineal Parenchymal Tumors of Intermediate Differentiation: A Case Report and Literature Review
    Samkari, Alaa M.
    Alshehri, Fayez D.
    Almehdar, Abeer S.
    Matar, Mutaz Y.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [8] Prognosticating survival of pineal parenchymal tumors of intermediate differentiation (PPTID) by grade
    Victor M. Lu
    Evan M. Luther
    Daniel G. Eichberg
    Alexis A. Morell
    Ashish H. Shah
    Ricardo J. Komotar
    Michael E. Ivan
    [J]. Journal of Neuro-Oncology, 2021, 155 : 165 - 172
  • [9] Pineal Parenchymal Tumors of Intermediate Differentiation Treated With Ventricular Radiation and Temozolomide
    Low, Justin T.
    Kirkpatrick, John P.
    Peters, Katherine B.
    [J]. ADVANCES IN RADIATION ONCOLOGY, 2022, 7 (01)
  • [10] Prognosticating survival of pineal parenchymal tumors of intermediate differentiation (PPTID) by grade
    Lu, Victor M.
    Luther, Evan M.
    Eichberg, Daniel G.
    Morell, Alexis A.
    Shah, Ashish H.
    Komotar, Ricardo J.
    Ivan, Michael E.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2021, 155 (02) : 165 - 172